Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response to nutrient intake, stimulating insulin secretion and suppressing glucagon release. GLP-1 agents exhibit promising therapeutic outcomes in treating type